China Resources Medical (1515.HK) shares fluctuated at a high level, rising 4.17% to HK $4.75, with a total market capitalization of HK $6.16 billion. According to GF Securities, the company's profit growth is expected to be better than that in the first half of the year, with a net profit of 4.49 yuan per 580 million yuan in 2021-23 and a target price of HK $8.55 at a target price of 8.55 Hong Kong dollars. China Merchants (Hong Kong) believes that National Healthcare Security Administration recently issued "National Healthcare Security Administration's notice on issuing a three-year action plan for the reform of DRG/DIP payment methods". Stocks such as China Resources Medical Services will benefit from the DRG/DIP reform to a large extent and will be given a buy rating with a target price of HK $11.70.